Need to Know
- The Nifty IPO Index touched an intraday 52-week high of 2,415 on Wednesday, August 26, even as the broader Nifty 50 slipped 0.52% to close at 24,207.75
- 56 mainboard companies have raised ₹82,895 crore via IPOs so far this year, keeping India’s primary market on a record pace
- At least 12 recently listed stocks have turned multibaggers, with gains touching as high as 407% over issue price
- Aditya Infotech (CP Plus) and Rubicon Research lead the pack, up roughly 428% and 227% from their issue prices in recent sessions
- Brokerages are now flagging Corona Remedies and Fujiyama Power Systems as the next names to watch for sustained upside
While the Sensex and Nifty 50 struggled to hold their gains on Wednesday, a quieter corner of the market was busy making investors rich.
The Nifty IPO Index, which tracks India’s most recently listed companies, surged to a fresh 52-week high of 2,415 in intraday trade, underscoring how aggressively money is chasing the country’s newest stock market entrants.
The move came on a day the Nifty Smallcap 100 also touched a 52-week high, even as heavyweight IT, FMCG, and auto counters dragged the headline indices lower.
What’s Driving the Rally
This isn’t a one-day accident. It’s the product of a primary market that has barely paused for breath. So far this year, 56 mainboard companies have collectively raised ₹82,895 crore through IPOs, keeping issuance on track for another blockbuster year after FY26 already saw mainboard listings cross the 100-issue mark for the first time since 2007.
That steady drumbeat has given the Nifty IPO Index a deep, growing bench of constituents, and a rising share of them now sit on outsized gains rather than modest listing-day pops.
Meet the Multibaggers
As many as 12 stocks that debuted in the past year have turned multibaggers, delivering returns of up to 407% over issue price. Several names are already familiar to traders tracking the primary market closely:
| Stock | IPO Price | Recent Price | Approx. Gain | Listed |
|---|---|---|---|---|
| Aditya Infotech (CP Plus) | ₹675 | ~₹3,566 (Aug 21) | ~428% | Aug 2025 |
| Rubicon Research | ₹485 | ~₹1,585 (Aug 10) | ~227% | Oct 2025 |
| Omnitech Engineering | ₹227 | ~₹586 (Aug 20) | ~158% | Mar 2026 |
| SEDEMAC Mechatronics | ₹1,352 | ~₹3,060 | ~126% | Mar 2026 |
| Shadowfax Technologies | ₹124 | ~₹248 | ~100% | Jan 2026 |
Figures are approximate as of the trade dates noted and move daily.
Topping the list is Aditya Infotech, the Noida-based surveillance equipment maker behind the CP Plus brand. The stock debuted at ₹1,015 against its ₹675 issue price last August and has since rallied as much as 428% over issue price as of its August 21 session, hitting a 52-week high near ₹3,965.
It got a fresh leg up last week after Motilal Oswal Financial Services initiated coverage with a ‘Buy’ rating, citing India’s thin video-surveillance penetration, just 1.1 CCTVs per 1,000 people versus 14.4 in China and 15.3 in the US, and a market expected to grow from ₹10,600 crore in FY25 to ₹22,700 crore by FY30.
Close behind is Rubicon Research, a US-focused pharma formulations company that has more than tripled from its ₹485 issue price on strong execution in regulated export markets.
Also Check: IPO Dashboard 2026 (SME & Main Board at NSE/BSE)
Sectors Behind the Surge
The common thread across this year’s Nifty IPO Index winners is exposure to structurally growing, under-penetrated sectors: surveillance, specialty pharma, precision engineering, mechatronics, and logistics tech.
Unlike earlier IPO cycles dominated by financials and consumer names, this year’s standout debutants sit in niche manufacturing and services businesses, a pattern analysts read as genuine post-listing earnings momentum rather than listing-day froth.
Corona Remedies, Fujiyama Power Systems: What’s Next
Not every recent IPO has crossed the multibagger threshold yet, but brokerages are flagging a few for continued upside.
Corona Remedies, the Gujarat pharma company that listed in December 2025 at a 38% premium to its ₹1,062 issue price, was trading roughly 62% above issue price as of June 5, on steady growth across women’s healthcare, cardiology, and pain management.
Fujiyama Power Systems, the Noida-based solar inverter maker that listed the same month, was up close to 76% over its ₹228 issue price as of July 13 on rapid capacity expansion. Neither has doubled yet, but both remain on analysts’ radar as candidates to join the multibagger list.
The FII-DII and Small-Cap Rotation Angle
This strength is playing out against a broader rotation in Indian equities. Foreign institutional investors bought shares worth ₹1,593.53 crore on Tuesday alone, taking their August tally to roughly ₹27,186 crore, while domestic institutions added ₹230.26 crore.
Notably, this buying has increasingly bypassed large-cap bellwethers for small- and mid-cap names, the same segment where most of this year’s IPO winners sit.
With the Nifty 50 nearly flat over the past year, growth-seeking investors have leaned harder into recently listed, sector-specific businesses, amplifying gains in the Nifty IPO Index relative to the broader market.
Track Live: FII DII DATA | NIFTYTRADER
What This Means Going Forward
The bigger question isn’t whether this year’s IPO crop has delivered; it clearly has, but whether the gains hold from current levels.
Aditya Infotech now trades at a price-to-earnings ratio north of 85 times, meaning further upside will likely depend on continued earnings delivery rather than multiple expansion alone.
For newer listings like Corona Remedies and Fujiyama Power Systems, the path to multibagger status hinges on execution, capacity commissioning, product launches, and margin trends over the next two to three quarters.
With thousands of crores’ worth of fresh mainboard IPOs still in the pipeline, the Nifty IPO Index’s constituent base and its volatility, is only set to expand further.
Read Next: HDFC Bank Gets 2 Fresh Triggers: 12 Stocks in Focus Today
Frequently Asked Questions
What is the Nifty IPO Index?
It tracks companies that have listed on the NSE mainboard within a defined recent window, giving investors a single gauge for how newly listed stocks are performing relative to the broader market.
Which IPO stock has given the highest return this year?
Aditya Infotech (CP Plus) has been a standout, rallying as much as 428% over its ₹675 issue price in recent sessions on strong earnings growth and rising analyst coverage.
Are Corona Remedies and Fujiyama Power Systems multibaggers yet?
Not yet. Corona Remedies is up about 62%, and Fujiyama Power Systems is about 76% over issue price as of their latest available trade data, both short of the 100% threshold, though brokerages see room for more gains.
Why is the Nifty IPO Index outperforming benchmark indices?
Record IPO issuance, strong post-listing earnings growth at several new companies, and a rotation of institutional capital toward small- and mid-caps have helped it outpace the relatively flat Nifty 50.
Is it safe to buy IPO stocks after such sharp rallies?
Not automatically. Several multibagger IPO stocks now trade at elevated valuations, so fresh allocation should weigh earnings visibility and risk appetite rather than past returns alone.
